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Letter Re: Development of a clinical decision support system for severity risk prediction 
and triage of COVD-19 patients at hospital admission: an international multicentre 
study. 
The covid-19 pandemic has led to a proliferation of clinical prediction models to aid diagnosis, 
disease severity assessment and prognosis. A systematic review has identified sixty-six covid-19 
prediction models – concluding all, with no exception, are at high risk of bias due to concerns 
surrounding the data quality, statistical analysis and reporting, and none are recommended for use [1]. 
Therefore, we read with interest the recent paper by Wu and colleagues describing the development of 
a model to identify covid-19 patients with severe disease on admission to facilitate triage [2].  
However, our enthusiasm was dampened by a number of concerns surrounding the design, analysis 
and reporting of the study which deserve highlighting to readers. 
Our first point relates to design. The authors randomly split their dataset in a training and test set. This 
been long been shown to be an inefficient use of the data [3] –reducing the size of the training set 
(increasing the risk of model overfitting), and creating a test set too small for model evaluation. There 
are alternative stronger approaches that use the entire data to both develop and internally validate a 
model based on cross-validation or bootstrapping [3]. This naturally leads us to further elaborate on 
the sample size. The sample size in a prediction model study is largely influenced by the number of 
individuals experiencing the event to be predicted (in Wu‟s study, those with severe disease). Using 
published sample size formulae for developing prediction models [4, 5], based on information 
reported in the Wu study (75 predictors, outcome prevalence of 0.237), then depending on the 
anticipated model R-squared, the minimum sample size in the most optimistic scenario (e.g., that the 
model gives the highest R-squared) would be 1285 individuals (306 events). To precisely estimate the 
intercept alone requires 279 individuals (66 events). After splitting their data, the authors developed 
their model with a sample size of 239 individuals (57 events) – clearly insufficient to estimate even 
the model intercept, let alone develop a prediction model.  
The test set was then used to evaluate the performance of their model comprising 60 individuals of 
whom ~14 experienced the event. To put this in perspective, current sample size recommendations to 
evaluate model performance suggest a minimum of 100 events [6]. The performance of the model was 
also evaluated separately in each of five external validation datasets where the number of events 
ranged from 7 to 98, all not meeting this minimum requirement. 
Other concerns include the handling of missing data; it is hard to believe all patients had complete 
information on all 75 predictors, and indeed the flow chart reveals 38 individuals with missing data 
were simply excluded, which can led to bias [7]. Continuous predictors were assumed to be linearly 
associated with the outcome, which can reduce predictive accuracy. Model overfitting (a clear 
concern given the small sample size) was not addressed either in adjusting the performance measures 
for optimism or shrinking the regression coefficients that are likely overestimated (e.g. using 
penalization techniques [8]). “Synthetic sampling” was used to address imbalanced data, but this is 
inappropriate since artificially balancing data will produce an incorrect estimation of the model 
intercept (unless it is re-adjusted post-estimation) leading to incorrect model predictions 
(miscalibration). Model performance was poorly and inappropriately assessed, including presenting a 
confusion matrix (inappropriate for evaluating prediction models [8]), reporting sensitivity/specificity 
(where net benefit would be more informative [9]), and assessing model calibration using weak and 
again discredited approaches  (e.g. Hosmer-Lemeshow test, rather than calibration plots with 
graphical loess curves [6]). We also question the arbitrary choice of risk groupings, and why 
individuals with a predicted risk of 0.21 are considered the same („middle risk‟) as those with a 
predicted risk of 0.80. 
Arguably the most important aspect of a prediction model article is the presentation of the model so 
that others can use or evaluate it in own their own setting. The authors have  presented a nomogram 
and (prematurely) linked to a web calculator. Whilst both these formats can be used to apply the 
model to individual patients (though given our concerns we urge against this), for independent 
validation the prediction model needs to be reported in full – namely all the regression coefficients 
and the intercept [10], but these are noticeably absent.  
Finally, the authors followed the STARD checklist for reporting their study – but this is not the 
correct guideline. STARD is for reporting diagnostic test accuracy studies, and not multivariable 
clinical prediction models. We urge the authors and other investigators developing (covid-19) 
prediction models to consult the TRIPOD Statement (www.tripod-statement.org) for key information 
to report when describing their prediction model study, so that readers have the minimal information 
required to judge the quality of the study [10].  The accompanying TRIPOD Explanation and 
Elaboration paper describes the rationale of the importance of transparent reporting, but also discusses 
various methodological considerations [6]. 
REFERENCES 
  1.  Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, Bonten MMJ, Damen 
JAA, Debray TPA, De Vos M, Dhiman P, Haller MC, Harhay MO, Henckaerts L, Kreuzberger N, 
Lohmann A, Luijken K, Ma J, Andaur Navarro CL, Reitsma JB, Sergeant JC, Shi C, Skoetz N, Smits 
LJM, Snell KIE, Sperrin M, Spijker R, Steyerberg EW, Takada T, van Kuijk SMJ, et al. Prediction 
models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ 2020; 
369: m1328. 
2.  Wu G, Yang P, Xie Y, Woodruff HC, Rao X, Guiot J, Frix A-N, Louis R, Moutschen M, Li J, 
Li J, Yan C, Du D, Zhao S, Ding Y, Liu B, Sun W, Albarello F, D‟Abramo A, Schininà V, Nicastri E, 
Occhipinti M, Barisione G, Barisione E, Halilaj I, Lovinfosse P, Wang X, Wu J, Lambin P. 
Development of a Clinical Decision Support System for Severity Risk Prediction and Triage of 
COVID-19 Patients at Hospital Admission: an International Multicenter Study. Eur Respir J 2020; : 
2001104. 
3.  Steyerberg EW, Harrell Jr FE, Borsboom GJJM, Eijkemans MJC, Vergouwe Y, Habbema 
JDF. Internal validation of predictive models: efficiency of some procedures for logistic regression 
analysis. J Clin Epidemiol 2001; 54: 774–781. 
4.  Riley RD, Ensor J, Snell KIE, Harrell FE, Martin GP, Reitsma JB, Moons KGM, Collins G, 
van Smeden M. Calculating the sample size required for developing a clinical prediction model. BMJ 
2020; 368: m441. 
5.  Riley RD, Snell KI, Ensor J, Burke DL, Harrell Jr FE, Moons KG, Collins GS. Minimum 
sample size for developing a multivariable prediction model: PART II - binary and time-to-event 
outcomes. Statistics in Medicine 2019; 38: 1276–1296. 
6.  Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, Vickers 
AJ, Ransohoff DF, Collins GS. Transparent Reporting of a multivariable prediction model for 
Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration. Ann Intern Med 2015; 
162: W1–W73. 
7.  Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter 
JR. Multiple imputation for missing data in epidemiological and clinical research: potential and 
pitfalls. BMJ 2009; 338: b2393. 
8.  Steyerberg EW. Clinical prediction models: a practical approach to development, validation, 
and updating. 2nd edition. New York: Springer; 2019. 
9.  Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of 
prediction models, molecular markers, and diagnostic tests. BMJ 2016; 352: i6. 
10.  Collins GS, Reitsma JB, Altman D, Moons KG. Transparent Reporting of a multivariable 
prediction model for Individual Prognosis Or Diagnosis: The TRIPOD statement. Ann Intern Med 
2015; 162: 55–63. 
 
 
 
 
